Bleeding Disorders
From the Journals
Women with FXI deficiency face hemorrhage risk with gyn surgery
The 20-year retrospective analysis found the highest proportion of bleeding after gynecologic surgery.
From the Journals
Study finds higher than expected rates of hemophilia in Indiana
The rise could be caused by increased use of prophylaxis and improvements in HIV care that are cutting mortality in the hemophilia population.
Feature
SB-525 gene therapy looks viable for hemophilia A
Two of eight patients treated with the investigational gene therapy SB-525 have achieved normal factor VIII levels, according to interim study...
Conference Coverage
Ticagrelor reversal agent looks promising
NEW ORLEANS – Ticagrelor’s antiplatelet effect was squelched within 5 minutes.
From the Journals
Novel assay unable to predict clinical severity in type 1 VWD
While the assay was effective in detecting von Willebrand disease, it did not perform well in assessing bleeding severity.
From the Journals
PK analysis shows benefit for rFVIII product in hemophilia A
Recombinant factor VIII product BAY 81-8973 (Kovaltry) provided a longer half-life and improved bleeding rates, compared with a sucrose-formulated...
From the Journals
Prophylaxis maintains high FIX trough levels in hemophilia B
Sustaining high FIX trough levels may successfully change a case of severe disease into a mild bleeding phenotype.
From the Journals
Hemophilia questionnaire proves valid around the globe
The questionnaire, that focused on patient-reported outcomes, has little variability based on region of the world.
From the Journals
Emicizumab may improve thrombosis management in hemophilia A
The case report offers real-world insights into treatment using emicizumab.
Commentary
A new era of TTP treatment
Many questions remain following the FDA’s approval of caplacizumab, specifically, which patients should receive it. The high cost of the drug is...
From the Journals
Weekly turoctocog alfa pegol is feasible for hemophilia A
An extension of the pathfinder 2 trial produced encouraging results with providing a stepped-down regimen in severe hemophilia A patients.